IMDNA • Neuroscience • Neurology • Neurobiology Research
Neurological Disease Research Assays
A Broad Molecular & Protein Research Platform Across the Neurological Disease Landscape
Neurological research spans disorders of the brain, spinal cord, peripheral nerves, and neuromuscular system, together with cerebrovascular, neuroimmune, neurodevelopmental, sleep-related, and neuro-oncologic conditions. IMDNA develops research assays that can be organized around the biology of each research question rather than a single universal neurological panel.
Programs can integrate RT-qPCR/qPCR for transcript-level and selected nucleic-acid research, ELISA for focused quantitative protein biomarker studies, and multiplex bead-based immunoassays for simultaneous cytokine, chemokine, and soluble-protein profiling.
From disease category to mechanism → analyte → assay → interpretable research data.
Disease Breadth
Broad Neurological Research Coverage
Neurodegenerative, vascular, seizure, demyelinating, peripheral nerve, neuromuscular, developmental, infectious, sleep, headache, movement, and neuro-oncology research.
Mechanisms
Pathway-Focused Biology
Neuroinflammation, neuronal injury, synaptic function, mitochondrial stress, proteostasis, myelin biology, vascular injury, immunity, and repair.
Technology
RNA + Protein Platforms
Choose RT-qPCR, ELISA, multiplex bead immunoassay, or a justified combination according to the analyte.
Assay Development
Custom Research Design
Build assays around disease model, specimen, target biology, study stage, longitudinal design, and analytical objective.
Translation
Biomarker & Response Research
Support mechanistic studies, candidate biomarker verification, molecular stratification, and experimental treatment-response research.
Neurological Research Landscape
The categories below are presented as a practical research-navigation framework rather than a rigid taxonomy. Neurological disorders frequently overlap categories—for example, Parkinson’s disease is both neurodegenerative and a movement disorder, while multiple sclerosis combines neuroimmunology, demyelination, and neuroaxonal injury.
1. Neurodegenerative Diseases
- Alzheimer’s disease
- Parkinson’s disease
- Amyotrophic lateral sclerosis (ALS)
- Huntington’s disease
- Dementia with Lewy bodies
- Frontotemporal dementia
Research themes: protein aggregation, RNA biology, synaptic dysfunction, axonal injury, mitochondria, lysosome/autophagy, neuroinflammation, neuronal loss.
2. Cerebrovascular Diseases
- Ischemic stroke
- Hemorrhagic stroke
- Transient ischemic attack (TIA)
- Brain aneurysm
- Arteriovenous malformation (AVM)
Research themes: vascular injury, thrombosis, endothelial biology, ischemia/reperfusion, inflammation, blood–brain barrier, neuronal injury, repair.
3. Epilepsy & Seizure Disorders
- Epilepsy
- Febrile seizures
- Status epilepticus
Research themes: neuronal excitability, synaptic signaling, ion-channel biology, inflammatory responses, injury after prolonged seizures, genetic mechanisms.
4. Demyelinating & Neuroimmune Diseases
- Multiple sclerosis
- Neuromyelitis optica spectrum disorder
- Acute disseminated encephalomyelitis (ADEM)
Research themes: immune activation, antibody/complement biology, T- and B-cell pathways, chemokine trafficking, myelin injury, astrocyte biology, neuroaxonal damage.
5. Headache Disorders
- Migraine
- Tension-type headache
- Cluster headache
- Trigeminal autonomic cephalalgias
Research themes: trigeminovascular signaling, neuropeptides, neurogenic inflammation, pain pathways, vascular and neuronal signaling.
6. Peripheral Nerve Disorders
- Peripheral neuropathy
- Guillain–Barré syndrome
- Carpal tunnel syndrome
- Bell’s palsy
- Chronic inflammatory demyelinating polyneuropathy (CIDP)
Research themes: axonal degeneration, Schwann-cell biology, immune-mediated demyelination, nerve injury, regeneration, inflammatory signaling.
7. Neuromuscular Disorders
- Myasthenia gravis
- Muscular dystrophies
- Spinal muscular atrophy
- Polymyositis
- Dermatomyositis
Research themes: neuromuscular-junction immunity, motor-neuron biology, muscle degeneration, dystrophin-associated pathways, inflammatory myopathy, genetic mechanisms.
8. Movement Disorders
- Essential tremor
- Dystonia
- Chorea
- Ataxia
- Tourette syndrome
Research themes: basal-ganglia and cerebellar pathways, neurotransmission, ion channels, synaptic signaling, genetic variation, neurodegeneration where applicable.
9. Neuroinfectious Diseases
- Meningitis
- Encephalitis
- Brain abscess
- Neurocysticercosis
Research themes: pathogen nucleic acids, host-response signaling, cytokines/chemokines, blood–brain barrier responses, CNS inflammation, tissue injury.
10. Neurodevelopmental & Congenital Neurological Conditions
- Cerebral palsy
- Spina bifida
- Hydrocephalus
- Neural tube defects
- Other investigator-defined neurodevelopmental disorders
Research themes: neurodevelopment, neural patterning, congenital structural biology, inflammation, genetics, neuronal maturation, repair and developmental signaling.
11. Sleep-Related Neurological Disorders
- Narcolepsy
- Restless legs syndrome
- REM sleep behavior disorder
Research themes: hypocretin/orexin biology, circadian and sleep-wake regulation, dopaminergic/iron-related pathways, neurodegeneration-associated prodromal biology.
12. Neuro-Oncology & Primary CNS Tumor Research
- Gliomas and other glial tumors
- Meningiomas
- Medulloblastoma and other embryonal CNS tumors
- Selected sellar-region tumors, where relevant to the research question
- Other primary brain and spinal cord tumors
Research themes: tumor genetics and epigenetics, oncogenic signaling, tumor–immune microenvironment, cell proliferation, angiogenesis, DNA-damage and repair pathways, molecular classification, and treatment-response research.
13. Other Neurological Disorders
- Trigeminal neuralgia
- Chiari malformation
- Normal-pressure hydrocephalus
- Functional neurological disorder
- Other investigator-defined neurological conditions
Research strategies depend strongly on mechanism; structural, functional, inflammatory, degenerative, pain, and CSF-dynamics disorders should not be forced into one biomarker model.
Research Programs Designed Around Biology—not Disease Names Alone
For neurological scientists, the most useful assay architecture often follows the mechanism being tested. The same pathway can appear across diseases, while the same clinical diagnosis may contain several biological subtypes.
Neurodegeneration & Proteinopathy
Applicable to Alzheimer’s disease, Parkinson’s disease, ALS, Lewy body disease, frontotemporal dementia, Huntington’s disease and related models.
- Protein aggregation and clearance
- RNA processing and splicing
- Autophagy/lysosomal pathways
- Mitochondrial quality control
- Synaptic and axonal injury
Neuroimmunology & Demyelination
Applicable to MS, NMOSD, ADEM, GBS, CIDP, myasthenia gravis and inflammatory neurological research.
- T- and B-cell activation
- Antigen presentation
- Interferon signaling
- Chemokine trafficking
- Myelin, astrocyte and axonal injury
Neurovascular & Ischemic Injury
Applicable to stroke, TIA, aneurysm, AVM and vascular-neurology research.
- Endothelial and vascular signaling
- Coagulation/thromboinflammatory research
- Hypoxia and ischemia-response pathways
- Blood–brain barrier biology
- Neuronal injury and repair
Seizure & Excitability Biology
Applicable to epilepsy, febrile seizures, status epilepticus and investigator-defined seizure models.
- Ion-channel and receptor pathways
- Synaptic excitation/inhibition
- Immediate-early response genes
- Neuroinflammatory responses
- Post-seizure injury and repair
Peripheral Nerve & Neuromuscular Biology
Applicable to neuropathy, GBS/CIDP, SMA, muscular dystrophy, inflammatory myopathy and neuromuscular-junction research.
- Axonal degeneration/regeneration
- Schwann-cell and myelin biology
- Muscle injury/remodeling
- Autoimmune and complement pathways
- Motor-neuron and neuromuscular signaling
Neuroinfection & Host Response
Applicable to meningitis, encephalitis, brain abscess, neuroparasitic disease and other CNS infection research.
- Pathogen-targeted qPCR where appropriate
- Host-response gene expression
- Cytokine/chemokine protein profiling
- Barrier and tissue-injury research
- Pathogen–host interaction studies
Neurodevelopment & Sleep Biology
Applicable to neurodevelopmental and congenital neurological conditions, narcolepsy, restless legs syndrome, REM sleep behavior disorder and mechanistic sleep research.
- Developmental gene programs
- Neuronal maturation
- Sleep-wake regulatory pathways
- Iron/dopaminergic biology where relevant
- Prodromal neurodegeneration research
Neuro-Oncology
Applicable to glioma and other glial tumors, meningioma, medulloblastoma and other embryonal CNS tumors, selected sellar-region tumors, and other primary brain or spinal cord tumor research.
- Oncogenic and tumor-suppressor pathways
- Gene-expression and molecular classification
- Tumor-immune microenvironment
- Angiogenesis and DNA repair
- Therapy-response research
Cross-Disease Molecular Pathway Modules
These modules allow investigators to compare mechanisms across disease categories without implying that any pathway is unique to one neurological disorder.
Neuronal / Axonal Injury
Neurofilament biology, cytoskeletal integrity, axonal transport, degeneration and repair-associated responses.
Synaptic Function
Synaptic vesicles, neurotransmission, excitatory/inhibitory balance and neuronal connectivity.
Neuroinflammation
Microglial, astrocytic, cytokine, chemokine, interferon and peripheral immune-response pathways.
Myelin & Glial Biology
Oligodendrocyte, Schwann-cell, astrocyte, demyelination and remyelination-associated programs.
RNA Processing & Splicing
RNA-binding proteins, alternative/cryptic splicing and transcript-processing mechanisms.
Proteostasis
Protein aggregation, ubiquitin–proteasome function, autophagy, lysosomal clearance and stress responses.
Mitochondrial Biology
Mitophagy, bioenergetics, oxidative stress and mitochondrial quality-control pathways.
Vascular / BBB Biology
Endothelial responses, vascular inflammation, permeability, ischemia and blood–brain barrier-associated biology.
Immune Trafficking
Antigen presentation, leukocyte activation, chemokines, adhesion and CNS immune-cell recruitment.
Cell Death & Repair
Apoptotic, stress, inflammatory, regenerative and tissue-repair pathways.
Genetic / Developmental Programs
Disease-associated genes, developmental pathways and investigator-defined inherited neurological mechanisms.
Tumor Biology
Cell-cycle, oncogenic signaling, immune microenvironment, angiogenesis, genomic alterations and DNA repair.
Integrated Technology Strategy
Technology should follow the analyte. Transcript abundance, pathogen nucleic acid, and soluble-protein concentration represent different analytical questions and require independent assay validation.
RT-qPCR / qPCR
Best suited for: targeted gene expression, selected splice variants, pathway signatures, genetic/nucleic-acid research, and pathogen targets where appropriate.
- Disease- and pathway-focused gene modules
- Neuroinflammatory expression signatures
- Splice-event research such as TDP-43-associated ALS biology
- Host-response and selected pathogen research
- Longitudinal molecular profiling
Development: follow MIQE 2.0 principles for assay design, efficiency, controls, normalization, analytical performance and transparent reporting.
ELISA
Best suited for: focused quantitative measurement of a soluble protein or small number of protein biomarkers.
- Neurofilament protein research
- GFAP and other glial/injury protein studies
- Selected cytokine or chemokine verification
- Focused neuroimmune protein studies
- Orthogonal verification of multiplex findings
Development: use fit-for-purpose ligand-binding assay validation including range, precision, selectivity, matrix effects, parallelism/recovery where meaningful, stability and lot performance.
Multiplex Bead-Based Immunoassay
Best suited for: simultaneous measurement of multiple cytokines, chemokines, growth factors and other soluble proteins.
- Neuroinflammatory network profiling
- Immune-mediated neurological disease research
- Host-response studies
- Exploratory multianalyte signatures
- Longitudinal treatment-response research
Development: evaluate each analyte in the multiplex context and control matrix effects, dynamic-range differences, cross-talk, lot/vendor effects, protocol adherence and inter-run variability.
Illustrative Research Biomarker Modules
Examples below show how assay content can be organized. They are not diagnostic signatures and should be selected and validated for the intended disease model, specimen and endpoint.
ALS / TDP-43 BiologySTMN2 splice biology, UNC13A cryptic splicing, TARDBP-associated pathways
Parkinson’s BiologySNCA, PINK1/PRKN, LRRK2/GBA1-associated mitochondrial and lysosomal pathways
MS / NeuroimmuneInterferon, antigen-presentation, T-cell, B-cell and chemokine modules
Neuroaxonal InjuryNfL/NfH protein research and related neuronal-injury pathways
Astroglial BiologyGFAP protein research and astrocyte-response pathways
Neurovascular InjuryEndothelial, BBB, hypoxia, inflammatory and repair-associated modules
Seizure BiologyIon-channel, neurotransmission, immediate-early and inflammation-associated modules
Peripheral NerveAxonal, myelin, Schwann-cell and immune-mediated nerve-injury modules
NeuromuscularNeuromuscular junction, muscle injury, inflammatory and inherited-pathway modules
NeuroinfectionPathogen qPCR plus host-response transcript/protein modules where scientifically appropriate
Neuro-OncologyTumor genetics, signaling, immune microenvironment and therapy-response modules
Custom NeurologyInvestigator-selected genes, proteins and pathways for disease-specific research questions
Best-Practice Assay-Development Pathway
A scientifically defensible neurological research program should be fit for purpose and should not make claims beyond the analyte, specimen, cohort and analytical platform actually evaluated.
| Stage | Best-Practice Approach | Scientific Rationale |
|---|
| 1. Define intended research use | Specify disease model, mechanism, specimen, analyte, comparator, sampling time and endpoint. | Prevents the assay platform from driving the biology. |
| 2. Select targets mechanistically | Use established disease biology, authoritative literature, discovery data and prespecified hypotheses. | Improves biological interpretability and reduces arbitrary biomarker assembly. |
| 3. Match analyte to technology | Use RT-qPCR for transcripts/nucleic acids, ELISA for focused protein measurement and multiplex bead assays for multianalyte protein profiling. | RNA, DNA and protein measurements answer different analytical questions. |
| 4. Define specimen compartment | Distinguish blood, serum, plasma, CSF, tissue, PBMC, sorted cells and cell-culture samples. | Peripheral and CNS compartments can show very different biology. |
| 5. Characterize analytical performance | Evaluate platform-specific specificity, precision, range, matrix effects, efficiency, controls and stability as applicable. | Prevents technical artifacts from being interpreted as biology. |
| 6. Verify biologically | Use appropriate controls, biological replication and longitudinal sampling where relevant. | Age, medication, comorbidity, disease stage and systemic inflammation can influence neurological biomarkers. |
| 7. Confirm orthogonally | Where useful, compare transcript and protein layers or confirm multiplex findings with focused assays. | Strengthens confidence that findings are not platform-specific artifacts. |
| 8. Validate independently | Lock candidate signatures/models and test in independent samples. | Independent validation is essential before broader generalization. |
Scientifically Responsible Interpretation
Neurological scientists work across unusually heterogeneous diseases and specimen compartments. Assay interpretation therefore requires disciplined separation of mechanism, analyte, platform and clinical phenotype.
- RT-qPCR measures nucleic-acid abundance; it does not directly measure protein concentration, neuronal death, vascular function or neurological disability.
- Neurofilament light is a broad neuroaxonal-injury biomarker and is not specific to one neurological disease.
- GFAP reflects astroglial biology/injury but is not a standalone disease-specific marker.
- Peripheral-blood signatures may reflect systemic immune-cell composition and should not automatically be interpreted as CNS tissue expression.
- Structural disorders such as Chiari malformation, hydrocephalus or carpal tunnel syndrome may require very different molecular research questions from inflammatory or degenerative diseases.
- Functional neurological disorder should not be represented as having an established molecular diagnostic signature; molecular research in this area remains distinct from established clinical diagnosis.
- CNS tumor research follows modern neuropathology and molecular-classification frameworks and should not be reduced to a generic “neurological biomarker panel.”
Important Category Note
The neurological landscape is not made of mutually exclusive boxes. Parkinson’s disease is both a neurodegenerative and movement disorder; REM sleep behavior disorder can be investigated in prodromal synucleinopathy research; inflammatory neuropathies bridge peripheral neurology and neuroimmunology; and primary CNS tumors are more appropriately addressed within neuro-oncology than within non-neoplastic neurology.
Therefore: IMDNA uses these categories for research navigation while designing assays around mechanisms and validated analytes.
From Neurological Disease Question to Interpretable Research Data
A rigorous neuroscience assay program connects disease biology, specimen choice, analyte selection, technology, analytical validation and independent biological confirmation.
Disease / Research Question
Mechanism / Pathway
Specimen & Analyte
Technology Selection
Optimization & QC
Biological Verification
Independent Validation
Custom Neurological Disease Assay Development
Neurological disease research rarely fits a universal panel. IMDNA can develop integrated research solutions using RT-qPCR/qPCR, ELISA, multiplex bead-based immunoassays, or a scientifically justified combination of these technologies.
Literature-informed biomarker selection
Disease- and pathway-focused modules
Primer & probe development
Splice-variant assay design
Multiplex RT-qPCR configuration
ELISA development & verification
Multiplex bead immunoassay design
Pathogen/host-response integration
Controls & normalization strategy
Analytical evaluation & technology transfer
Why Neurological Researchers Work with IMDNA
Broad Neuroscience ScopeSupport neurological research across CNS, peripheral nerve, neuromuscular, neuroimmune, vascular, developmental, infectious, sleep and tumor biology.
Mechanism FirstBuild around neuronal injury, immunity, synapses, myelin, mitochondria, proteostasis, vascular biology, genetics or tumor pathways.
Multi-TechnologySelect RNA or protein platforms according to the biological question.
CustomizableUse disease names as research context—not as a rigid panel boundary.
Scientifically ConservativeSeparate exploratory research from clinically validated diagnostic or prognostic claims.
Scientific Foundation & Authoritative Frameworks
-
World Health Organization (WHO) — Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders 2022–2031.
WHO provides a broad public-health framework for neurological disorders and neurological health, including major areas such as epilepsy, cerebrovascular disease, headache disorders, neurodegenerative conditions, neuroinfectious and neuroimmunological disorders, neuromuscular disorders, neurodevelopmental disorders, traumatic neurological injury, and cancers affecting the nervous system.
Official WHO publication
-
National Institute of Neurological Disorders and Stroke (NINDS) — Neurological Disorders Information.
NINDS maintains authoritative disease information and research resources across a wide spectrum of neurological conditions affecting the brain, spinal cord, peripheral nerves, and neuromuscular system. The NINDS disorder directory supports the broad neurological research scope represented on this page without implying that all conditions share the same biology or biomarker strategy.
Official NINDS disorders directory
-
National Cancer Institute (NCI) — Brain and Central Nervous System Tumors.
NCI provides authoritative information on primary brain and spinal cord tumors and recognizes multiple CNS tumor types, including gliomas, ependymal tumors, medulloblastoma and other embryonal tumors, meningeal tumors, germ-cell tumors, and additional primary CNS neoplasms. NCI resources also distinguish primary CNS tumors from metastatic tumors involving the brain.
Official NCI brain and CNS tumor resource
NCI Adult Central Nervous System Tumors Treatment (PDQ®)
-
MIQE 2.0 — Quantitative PCR Research Quality Framework.
The updated MIQE framework provides current guidance for qPCR and RT-qPCR research, including preanalytical considerations, assay design and validation, controls, amplification performance, normalization, analytical range, data analysis, and transparent reporting.
MIQE 2.0, Clinical Chemistry (2025)
-
Fit-for-Purpose Biomarker Assay Development.
Biomarker methods should be developed and validated according to their intended research use. The extent of analytical characterization should be appropriate to the biological question, specimen matrix, assay platform, and way the resulting data will be interpreted.
Lee JW et al., Pharmaceutical Research (2006)
-
Multiplex Ligand-Binding Assay Validation.
Multiplex bead-based immunoassays require analyte-specific evaluation because dynamic range, matrix interference, parallelism, cross-reactivity, stability, and assay performance can differ among analytes within the same multiplex panel.
Jani D et al., AAPS Journal (2016)
Scope of these references: WHO and NINDS support the broad neurological-disease framework used for research navigation; NCI supports the neuro-oncology and primary CNS tumor section; MIQE 2.0 supports qPCR/RT-qPCR assay-quality principles; and the fit-for-purpose biomarker references support analytical development of ELISA and multiplex ligand-binding assays. These sources do not imply endorsement of IMDNA or establish any IMDNA assay as diagnostic. Disease categories can overlap, and example biomarkers or pathways on this page are research-oriented rather than disease-specific diagnostic signatures.
Build a Neurological Disease Research Solution Around Your Study
Whether your work focuses on neurodegeneration, stroke, epilepsy, demyelination, headache, peripheral neuropathy, neuromuscular disease, movement disorders, neuroinfection, development, sleep, neuro-oncology, structural neurological disease, biomarker discovery, or treatment-response research, IMDNA can develop a focused assay strategy around the mechanism and analytes that matter to your study.
Discuss Your Neurological Disease Research Project with IMDNA
For Research Use Only (RUO). Not for use in diagnostic procedures. Research findings require appropriate analytical and biological validation before any clinical interpretation.